Anti-Asthmatics And COPD Drugs Global Market Report 2022Including: 1) By Type: Anti-histamine Drugs; long-acting ?2-agonists (LABA); Inhaled corticosteriods; Short-acting muscarinic receptor antagonists (SAMAs); Other Anti-Asthmatics And COPD Drugs ( – Yahoo Finance

Major players in the anti-asthmatics and COPD drugs market are Novartis AG, Merck & Co. , GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura, Pfizer and Abbott.
New York, March 16, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Anti-Asthmatics And COPD Drugs Global Market Report 2022Including: 1) By Type: Anti-histamine Drugs; long-acting ?2-agonists (LABA); Inhaled corticosteriods; Short-acting muscarinic receptor antagonists (SAMAs); Other Anti-Asthmatics And COPD Drugs (" –

The global anti-asthmatics and copd drugs market is expected to grow from $80.73 billion in 2021 to $88.18 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $118.78 billion in 2026 at a CAGR of 7.7%.

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

The main classes of drugs in anti-asthmatics and chronic obstructive pulmonary disease (COPD) are bronchodilators, anti-inflammatory drugs, monoclonal antibodies, combination drugs.A bronchodilator, also known as a broncholytic, is a drug that stimulates the bronchi and bronchioles, reducing respiratory airway resistance and boosting lung airflow.

The different types include anti-histamine drugs, long-acting ?2-agonists (laba), inhaled corticosteriods, short-acting muscarinic receptor antagonists (samas), other anti-asthmatics and copd drugs (including combinations). The several end users include asthma patients, COPD patients and distributed through various channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, e-commerce.

North America is the largest region in the anti-asthmatics and COPD drugs market in 2021.Middle East is expected to be the fastest growing region in the forecast period.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market.Even though there is a decreasing trend of smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence.

For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high income countries including USA and Europe. According to WHO, in developed countries more than 35% of total energy requirement is derived from fats when compared to <20% in low income countries, and <25% in lower middle income countries.

Developing the patent expiration of innovator drugs is restricting the anti-asthmatics and COPD drugs market.Due to patent expiration, generic drugs are entering the market which is inexpensive when compared to innovator drugs.

For example, the patent for roflumilast tablets expired in January 2020.Daliresp, roflumilast tablets are a prescription medication meant for patients with severe COPD to reduce the number of episodes of COPD.

Therefore, developing patent expiration of innovator drugs is expected to hamper the growth of the anti-asthmatics and COPD drugs market over coming years.

The use of combination drugs for the treatment of asthma and COPD is increasing.This is due to the greater impact on patient reported outcomes (PROs) compared to monotherapies.

For example, combination of short acting beta agonists (SABA) and short acting muscarinic antagonists (SAMA) are superior compared to either medication alone in improving lung function. The use of combination long-acting beta agonists (LABA), and long acting muscarnic antagonists (LAMA) have improved lung function than long-acting monotherapy bronchodilators.

Many inhalers that do not use chlorofluorocarbons (CFC) are already available for the treatment of asthma and chronic obstructive pulmonary disease.These products aren’t necessarily official direct alternatives to CFC Metered Dose Inhalers, but may in many patients serve as a useful medication that could replace the need for a particular CFC Metered Dose Inhaler.

FDA will determine official alternatives by using the criteria established through notice-and-comment rulemaking.

The countries covered in the anti-asthmatics and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk posted in a Twitter thread on Monday advising followers to own “physical things” when inflation is high. In the tweet, Musk said “As a general principle, for those looking for advice from this thread, it is generally better to own physical things like a home or stock in companies you think make good products, than dollars when inflation is high. I still own & won’t sell my Bitcoin, Ethereum or Doge fwiw.” The biggest takeaway for some followers seems to ha
What happened Electric vehicle (EV) stocks are volatile by nature. Most EV companies aren't yet profitable, and much of investors' excitement is built on hope and potential. But recent volatility hasn't been driven by the underlying business or market potential.
Great Hill Capital Chairman Thomas Hayes sits down with Yahoo Finance Live to talk about the surge in China's internet companies, China's past tech crackdowns, and the forecasts for Chinese stocks like Alibaba.
Yahoo Finance Live's Jared Blikre breaks down how Chinese stocks are trading.
Shares of Chinese internet giants Baidu (NASDAQ: BIDU), Tencent Holdings (OTC: TCEHY) and Pinduoduo (NASDAQ: PDD) were rocketing skyward on Wednesday, up 25.9%, 25.8%, and — wait for it — 43.6%, respectively, as of 1:16 p.m. ET. Of course, they also come after an unprecedented losing streak for Chinese stocks over the past week. Chinese stocks have been wrecked by a combination of factors.
Turns out, no sooner did Lockheed Martin get some good news — than some bad news followed. Lockheed Martin's F-35 — here viewed head-on — could be a headache for Lockheed Martin today. On Monday this week, as you may have heard, Lockheed Martin investors were thrilled to learn that the German Luftwaffe is planning to purchase as many as 35 new F-35 stealth fighter jets from Lockheed Martin, to replacing its aging Tornado fighter-bombers.
Fast-food chain Wendy's wants to do something that Chipotle has done but McDonald's has struggled with.
Yahoo Finance Live's Brad Smith outlines the latest takeover bids proposed towards retailer Kohl's.
An economy challenged by inflation and a market preparing for interest rate hikes have been made worse by Russia's invasion of Ukraine and the turmoil and uncertainty that has caused. In uncertain times, it's hard to know where to turn, but a good place to start might be with one of the world's greatest investors, Warren Buffett, founder and CEO of Berkshire Hathaway. A look at where Buffett and Berkshire are investing their money could prove illuminating for many investors.
News from China, the Russia-Ukraine war and the Federal Reserve spurred a big market rally. But don't get too excited yet.
Shares of e-commerce and cloud-computing behemoth Amazon (AMZN) have been volatile as of late, following news that the stock is getting a 20-for-1 split. That's a huge deal that will open the door to a new world of small retail investors. Indeed, splits for big tech has been some sort of trend lately, and Amazon is jumping aboard the bandwagon. Amazon's Split and Share Repurchase Ignite a Bounce Although splits are ultimately good for retail investors, they don't add value for existing sharehold
In this article we are going to estimate the intrinsic value of Imperial Petroleum Inc. ( NASDAQ:IMPP ) by estimating…
Zach Griffiths, Wells Fargo Senior Macro Strategist, and Gregory Daco, EY-Parthenon Chief Economist, join Yahoo Finance Live to discuss whether the Fed's projected rate hikes were priced into the market.
SoFi's acquisition of Technisys could reap long-term benefits as the company continues building a best-in-class tech stack.
What happened  Shares of NortonLifeLock (NASDAQ: NLOK) fell hard today after U.K. regulators said they were investigating the company's proposed merger with rival cybersecurity company Avast.  The tech stock was down by 13% at the end of the trading day.
Japanese accountant Masamitsu has not travelled or gone to the cinema in years and rarely eats out. Instead, his annual salary of about $34,000 goes to support his family and has risen by just $4 a year for nearly a decade. Masamitsu's plight mirrors that of many workers at small and medium-sized firms in Japan, where the average salary in 2020 was $38,515, little changed from the 1990s and well below the average of $49,165 in countries of the Organisation for Economic Cooperation and Development (OECD).
The Federal Reserve will raise rates. Do you know how to trade the S&P 500 and Nasdaq afterwards? Here are the key levels to know now.
Rivian investors have been bullish over the past two days, but there's much more work to be done.
Shares of Incannex Healthcare (NASDAQ: IXHL) were crashing 58.4% lower as of 3:52 p.m. ET on Wednesday. The huge decline came after the Australian drugmaker announced earlier today the issuance of 1.85 million shares related to the exercise of unlisted stock options. The addition of 1.85 million shares makes up less than 4% of Incannex Healthcare's outstanding shares.
India is preparing to buy heavily discounted crude oil from its long-time ally Russia. While this may not be much, a discount on Russian crude will surely lower India’s import bill, The Times of India reported today (March 16). Every 10% increase in crude oil prices would lead to a 0.3 percentage point-widening in India’s current account deficit (CAD), and in turn, a weaker rupee, Nomura Research said in a report recently.


Add a Comment

Your email address will not be published. Required fields are marked *